CuriRx, a contract development and manufacturing organization (CDMO) located in Wilmington, MA, has launched the Advanced Bioprocessing and Analytical Center. Led by CuriRx’s team of industry experts and state-of-the-art bioprocessing laboratories combined with the CuriLytics Platform’s high-resolution analytical instrumentation, the Advanced Bioprocessing and Analytical Center provides end to end support to developers of biotherapeutics.

Modern biopharmaceutical drugs, such as recombinant proteins, monoclonal antibodies (mAb), bispecific antibodies, vaccines, antibody drug conjugates (ADCs), oligonucleotides, and gene therapy products (e.g., AAV’s) are very complex molecules with long development timelines and significant challenges.

CuriRx says its Advanced Bioprocessing and Analytical Center offers the ability to accelerate biotherapeutic drug development and overcome challenges by leveraging their team’s decades of bioprocessing experience and the latest methods in upstream and downstream process development. Biotherapeutic drug development is further de-risked with the combination of the CuriLytics Platform, using high-resolution mass spectrometry and a battery of orthogonal characterization methods.

“We are excited to assist our clients in accelerating their drug development programs,” said Indu Javeri, CEO, CuriRx. “The Advanced Bioprocessing and Analytical Center along with our formulation, lyophilization and analytical testing services provides complete end to end support.”

As a CDMO CuriRx provides upstream and downstream processes development, optimization, and characterization, scale-up and scale down, analytical development, formulation development, lyophilization and more.